| EDITAS MEDICINE DL-,0001 |
| USA |
| Gesundheit |
| US28106W1036 / A2AC4K |
| 8EM (Frankfurt) / EDIT (NASDAQ) |
| FRA:8EM, ETR:8EM, 8EM:GR, NASDAQ:EDIT |
| - |
| https://www.editasmedicin.. |
|
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company’s work centers on CRISPR-based technologies, including Cas9 and Cas12a, which it uses to design precise..
>Volltext.. |
| 348.53 Mio. EUR |
| 242.45 Mio. EUR |
| 44.92 Mio. EUR |
| -73.11 Mio. EUR |
| -65.11 Mio. EUR |
| -0.56 EUR |
| 63.79 Mio. EUR |
| 83.99 Mio. EUR |
| -99.35 Mio. EUR |
| 2.66 |
| 11.28% |
| 62.56% |
| - |
| - |
| - |
| EDITAS |
| 14.11.26 |
|
||||
|